OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
51
Results
Show all
Save search
Copy query
Show results for
Unknown
(51)
Publication Date
Release Date
2024
(7)
2022
(7)
2017
(6)
2023
(5)
2010
(5)
2011
(4)
2021
(3)
2018
(3)
2016
(3)
2025
(2)
2013
(2)
2026
(1)
2015
(1)
2012
(1)
2008
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
Evolution of a Plasmid Regulatory Circuit Ameliorates Plasmid Fitness Cost.
Not available
S-EPMC11997246
|
biostudies-literature
Cite
Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence.
Not available
S-EPMC9169424
|
biostudies-literature
Cite
The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence.
Not available
S-EPMC9167683
|
biostudies-literature
Cite
Changes in Distribution of Severe Neurologic Involvement in US Pediatric Inpatients With COVID-19 or Multisystem Inflammatory Syndrome in Children in 2021 vs 2020.
Not available
S-EPMC9641594
|
biostudies-literature
Cite
Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder.
Not available
S-EPMC6117612
|
biostudies-literature
Cite
The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2-associated multisystem inflammatory syndrome in children.
Not available
S-EPMC9797337
|
biostudies-literature
Cite
Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.
Not available
S-EPMC8220972
|
biostudies-literature
Cite
HNRNPC haploinsufficiency affects alternative splicing of intellectual disability-associated genes and causes a neurodevelopmental disorder.
Not available
S-EPMC10432175
|
biostudies-literature
Cite
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Not available
S-EPMC11299415
|
biostudies-literature
Cite
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Not available
S-EPMC4486345
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets